Table 4.
MTT assay IC50 values derived for qHTS screen data for oncology drugs on parental and isogenic SUM149 cells.
| Primary IC50 ± SD (μM) | |||
|---|---|---|---|
| SUM149 | rSUM149 | rrSUM149 | |
| Fludarabine | 2.1 ± 1.1 | 1.7 ± 0.8 | 1.4 ± 0.9 |
| Mitoxantrone | 2.5 ± 0.6 | 11.4 ± 1.3 | 3.8 ± 3.4 |
| Sorafenib | 4.5 ± 0.4 | 14.6 ± 3.1 | 78 ± 16 |
| Sunitinib | 5.0 ± 0.8 | >25 | 7.05 ± 6.3 |
| Gefitinib | 6.2 ± 2.3 | >50 | 28 |
| Vorinostat | 8.9 ± 4.9 | 6.2 ± 0.6 | 2.75 ± 2.1 |
| Lapatinib | 9.0 ± 0.3 | >50 | 9.1 |
| Mitomycin | 9.1 ± 0.4 | 18.5 ± 0.8 | 6.2 ± 0.4 |
| Bleomycin | 13.8 ± 2.0 | >50 | 9.5 |
| Capecitabine | 15.0 ± 9.5 | >50 | 26 ± 1.4 |
Doxorubicin, bortezomib, dactinomycin, plicamycin and daunorubicin all had IC50 values <0.2 μM on all three isogenic cell lines.